Search

everythinglearnresearchcommunity

for

Search:↓

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Platelet-rich plasma may successfully treat lichen planopillaris, as shown by one patient's symptom regression.

Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.

Retinol with polylysine cleared scalp skin growths in 21 days without side effects.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Budesonide alone is less effective than standard treatment for autoimmune hepatitis.

Biomimetic nanovesicles can speed up diabetic wound healing by regulating immune cell behavior and metabolism.

The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

A Japanese man with rare skin conditions improved with hydroxychloroquine treatment.

Valproic acid treatment may cause temporary hair loss due to reduced zinc and biotinidase levels, which tend to normalize after 6 months.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

New treatments for skin conditions in children include a preferred drug for birthmark reduction, proactive creams for eczema and vitiligo, a safe psoriasis medication, and special tissues and socks for eczema and fungal infections.

Cannabinoids may help manage epidermolysis bullosa symptoms, but more research is needed.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Tofacitinib may help treat hair loss in children with alopecia areata.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

A small group of slow-growing cells causes basal cell carcinoma to return after treatment.